Parthenolide is selectively toxic to leukemia cells; however, it also activates cell protective responses that may limit its clinical application. Therefore, we sought to identify agents that synergistically enhance parthenolide's cytotoxicity. Using a highthroughput combination drug screen, we identified the anti-hyperglycemic, vildagliptin, which synergized with parthenolide to induce death of the leukemia stem cell line, TEX (combination index (CI) ¼ 0.36 and 0.16, at effective concentration (EC) 50 and 80, respectively; where CI o1 denotes statistical synergy). The combination of parthenolide and vildagliptin reduced the viability and clonogenic growth of cells from acute myeloid leukemia patients and had limited effects on the viability of normal human peripheral blood stem cells. The basis for synergy was independent of vildagliptin's primary action as an inhibitor of dipeptidyl peptidase (DPP) IV. Rather, using chemical and genetic approaches we demonstrated that the synergy was due to inhibition of the related enzymes DPP8 and DPP9. In summary, these results highlight DPP8 and DPP9 inhibition as a novel chemosensitizing strategy in leukemia cells. Moreover, these results suggest that the combination of vildagliptin and parthenolide could be useful for the treatment of leukemia.
INTRODUCTION
Acute myelogenous leukemia (or acute myeloid leukemia; AML) is a heterogeneous group of aggressive malignant diseases characterized by the clonal expansion of undifferentiated myeloid precursors (that is, blasts). 1 AML induction chemotherapy, consisting of 3 days of daunorubucin (45-90 mg/m 2 ) and 7 days of continuous intravenous infusions of cytarabine (100 mg/m 2 ), results in complete response rates up to 80%; 2 however, the majority of patients ultimately relapse. 3 Thus, there is a need for improved chemotherapeutics.
Parthenolide, the bioactive component of the medicinal plant Feverfew (Tanacetum parthenium), is a sesquiterpene lactone with specific toxicity to AML cells compared with normal hematopoietic cells. 4 The mechanism of parthenolideinduced death appears multi-factorial. Parthenolide has been shown to inhibit NFkB activation, 5 increase reactive oxygen species, 5, 6 inhibit STAT3 activation 7 and increase p53 phosphorylation. 8 However, parthenolide also induces anti-oxidant, cellular protective responses that likely reduce its overall cytotoxicity, such as increases in the transcription factor NF-E2-related factor 2 and its transcriptional target heme oxygenase 1. 9 Here, we sought to identify agents that synergistically enhance parthenolide's cytotoxicity. Specifically, we screened an in-house library of on-patent and off-patent drugs for agents that increased the cytotoxicity of parthenolide. From this screen, we identified vildagliptin, an oral antihyperglycemic agent.
MATERIALS AND METHODS

Cell culture
Leukemia (OCI-AML2, TEX) and lymphoma cell lines (OCI-Ly17) were cultured in Iscove's Modified Dulbecco's Medium (IMDM). TEX cells (a gift from Dr J. Dick, Toronto, Ontario, Canada) were maintained in IMDM, 15% fetal bovine serum (FBS), 1% penicillin-streptomycin, 2 mM L-glutamine, 20 ng/ml stem cell factor, 2 ng/ml interleukin-3. Unless otherwise noted, all media were supplemented with 10% FBS, 100 units/ml of streptomycin and 100 mg/ml of penicillin (all from Hyclone, Logan, UT, USA). Cells were incubated in a humidified air atmosphere containing 5% CO 2 at 37 1C.
Primary human AML samples were isolated from the peripheral blood of consenting AML patients, who had at least 80% malignant cells in their peripheral blood and cultured at 37 1C in IMDM, 20% fetal calf serum, 100 units/ml of streptomycin and 100 mg/ml of penicillin. Normal granulocyte colony stimulating factor (GCSF)-mobilized peripheral blood mononuclear cells were obtained from volunteers donating peripheral blood stem cells for allotransplant. The collection and use of human tissue for this study was approved by the local ethics review board (University Health Network, Toronto, Ontario, Canada).
High-throughput screen
A high-throughput screen was performed as previously described. 10, 11 Briefly, TEX cells (1.0 Â 10 4 /well) were seeded in 96-well polystyrene tissue culture plates. After seeding, cells were treated with aliquots (10 mM final concentration) of the chemical library with a final dimethyl sulfoxide (DMSO) concentration of 0.05%. After 72 h incubation, cell proliferation and viability were measured by the MTS assay. Liquid handling was performed by a Biomek FX Laboratory Automated Workstation (Beckman Colter).
Cell growth and viability
Cell growth and viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS) reduction assay (Promega, Madison, WI, USA), according to the manufacturer's protocol and as previously described. 11 Cells were seeded in 96-well plates and treated with drug for 72 h. Optical density was measured at 490 nm. Cell viability was also assessed by the trypan blue exclusion assay and by Annexin V and propidium iodide (PI) staining (Biovision, Mountainview, CA, USA), as previously described.
11
Clonogenic growth assays with primary AML cells were performed, as previously described. 11 Briefly, primary AML mononuclear cells were isolated by Ficoll separation (Histopaque-1077, Sigma-Aldrich, St Louis, MO, USA) from fresh peripheral blood samples of AML patients with 480% blasts in their peripheral blood. Fresh AML mononuclear cells (4 Â 10 5 cells/ml) were incubated with vehicle control, parthenolide (5 mM), vildagliptin (10 mM), or parthenolide and vildagliptin for 48 h, washed and then plated in duplicate by volume at 10 5 cells/ml per 35 mm dishes (Nunclon, Rochester, NY, USA) in MethoCult GF H4434 medium (StemCell Technologies, Vancouver, British Columbia, Canada) containing 1% methylcellulose in IMDM, 30% FBS, 1% bovine serum albumin, 3 U/ml recombinant human erythropoietin, 10 À 4 M 2-mercaptoethanol, 2 mM L-glutamine, 50 ng/ml recombinant human stem cell factor, 10 ng/ml recombinant human granulocyte macrophage-colony stimulating factor and 10 ng/ml recombinant human interleukin-3. After 7 days of incubation at 37 1C with 5% CO 2 and 95% humidity, the numbers of colonies were counted on an inverted microscope. A cluster of 10 or more cells were counted as one colony.
Drug combination studies
The combination index (CI) was used to evaluate the interaction between parthenolide and vildagliptin. TEX cells were treated with increasing concentrations of parthenolide or vildagliptin and 72 h after incubation cell viability was measured by the MTS assay. The Calcusyn median effect model was used to calculate the CI values and evaluate whether the combination of parthenolide and vildagliptin was synergistic, antagonistic or additive. CI values of o1 indicate synergism, CI ¼ 1 indicate additivity and CI 41 indicate antagonism. 12, 13 Quantitative real-time PCR First-strand complementary DNA was synthesized from 1 mg of DNasetreated total cellular RNA using random primers and SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's protocols. Real-time PCR assays were performed in triplicate with 5 ng of RNA equivalent complementary DNA, SYBR Green PCR Master mix (Applied Biosystems, Foster City, CA, USA) and 400 nM of gene-specific primers. Reactions were processed and analyzed on an ABI 7900 Sequence Detection System (Applied Biosystems 0 -ggacatctaagggcatcaca-3 0 . Relative mRNA expression was determined using the DDCT method as previously described. 14 Surface DPP activity and the presence of DPIV/CD26 Surface activity of DPP in leukemia and lymphoma cell lines was determined using the Gly-Pro-p-nitroanalide substrate (Sigma-Aldrich), as previously described. 15 Briefly, cells were washed in PBS and whole-cell suspensions (5 Â 10 5 cells/200 ml in PBS) were prepared and placed in 96-well plates. Gly-Pro-p-nitroanalide substrate, which is converted to p-nitroanalide in the presence of DPP enzymes, was then added to a final concentration of 0.24 mM. The suspension was measured spectrophotometrically at 405 nm at 37 1C at 0 and 60 min. DPP enzyme activity was calculated from the increase of absorption between 0 and 60 min.
Surface CD26 expression was measured by flow cytometry. Cells (5.0 Â 10 5 ) were suspended in 1 ml PBS þ 0.05% FBS and incubated with an anti-CD26/DPPIV monoclonal antibody at 37 1C for 45 min and read on a FACS Calibur (BD Biosciences, Franklin Lakes, NJ, USA).
RNAi knockdown of DPP8 and DPP9
Lentiviral infections were performed as described by Xu et al 16 . Briefly, OCI-AML 2 cells (5 Â 10 6 ) were centrifuged and resuspended in 6.5 ml media containing protamine sulfate (5 mg/ml) and 1 ml of virus cocktail (which contains the short hairpin RNA (shRNA) sequence and a puromycin antibiotic resistance gene) and incubated overnight at 37 1C. 
Engraftment assay
Engraftment assays were performed similar to previously described. 10 Briefly, a CD34 þ AML patient sample was treated ex vivo with 10 mM vildagliptin, 2.5 mM parthenolide, a combination of these two agents or DMSO control for 24 h at 37 1C and 5% CO 2 . Cells were then injected into the right femur of sub-lethally irradiated NOD/SCID mice. Following a 4-week period, mice were killed and the left bone marrow flushed. Marrow engraftment of AML cells was assessed by measuring the percentage of human CD45
þ /CD19 À /CD33 þ cells by flow cytometry.
Statistical analysis
Unless otherwise stated, the results are presented as mean±s.d. Data were analyzed using GraphPad Prism 4.0 (GraphPad software, La Jolla, CA, USA). Pp0.05 was accepted as being statistically significant. Drug combination data were analyzed using Calcusyn software (Biosoft, Cambridge, UK).
RESULTS
A screen of on-patent and off-patent drugs for compounds that enhance parthenolide's anti-leukemic activity identifies vildagliptin To identify agents that synergistically enhance the cytotoxicity of parthenolide, we screened an in-house chemical library of 313 onpatent and off-patent drugs focused on anti-microbials and metabolic regulators with a wide therapeutic index and wellcharacterized pharmacokinetics. TEX leukemia cells were treated with aliquots of the chemical library (final concentration 10 mM) with or without parthenolide at its EC 30 concentration (2.5 mM; Supplementary Figure 1 ). After 72-h incubation, cell growth and viability was assessed using the MTS assay. The top six library compounds with the greatest reduction in viability when in combination with parthenolide were then assessed in secondary confirmatory assays (Supplementary Figure 2) . As we were interested in drug synergy, library compounds that imparted 450% toxicity in the absence of parthenolide were excluded as possible hits. Therefore, the compound with the greatest reduction in viability when in combination with parthenolide was vildagliptin ( Figure 1a ). Synergy between vildagliptin and parthenolide was validated using the CI analysis ( Figure 1b ). The combination of parthenolide and vildagliptin synergistically reduced growth and viability with CI values of 0.64, 0.36 and 0.16, at EC 30, 50 and 80, respectively. In addition, we confirmed reductions in growth and viability using the MTS assay and demonstrated the drug combination increased cell death by Annexin V/PI staining ( Figure 1c ). We also evaluated the combination of parthenolide and vildagliptin in OCI-AML2 leukemia cells. Similar to the effects in TEX cells, the combination of vildagliptin and parthenolide inhibited cell growth greater than either agent alone ( Figure 1d ). A two-way analysis of variance (ANOVA) confirmed a significant interaction between the main effects of vildagliptin and parthenolide (Po0.001).
Vildagliptin's ability to enhance the cytotoxicity of common clinical therapeutics was also assessed. Here, vildagliptin (10 mM) was incubated with increasing concentrations of cytarabine (Ara C), doxorubicin or vinblastine for 72 h in TEX cells. Cell growth and viability was determined using the MTS assay. Vildagliptin did not enhance the cytotoxicity of these chemotherapeutics (Figure 1e ).
Therefore, vildagliptin appears to selectively enhance the cytotoxicity of parthenolide.
Vildagliptin enhances parthenolide's cytotoxicity in primary AML patient samples The ability of vildagliptin to enhance parthenolide's cytotoxicity was also evaluated in primary AML patient samples and normal hematopoietic cells. Primary cells were treated for 24 h with vildagliptin, parthenolide or a combination of the drugs. After incubation, cell viability was measured by Annexin V and PI staining. Vildagliptin enhanced parthenolide's cytotoxicity in five primary AML patient samples (Figures 2a and b) . A two-way ANOVA confirmed significant interaction effects between vildagliptin and parthenolide (Po0.05). In addition, we demonstrated enhanced cytotoxicity with the drug combination in the CD34 þ /CD38 À fraction of AML stem cells (Figure 2b ). In contrast to the effects on the malignant cells, the combination had less effect on the viability of normal hematopoietic cells. Two of three tested samples showed no increase in toxicity with the drug combination (P40.05 by two-way ANOVA), whereas a third sample showed only a small enhancement (Figure 2c) . Thus, the combination of vildagliptin and parthenolide appeared to selectively target AML cells over normal hematopoietic cells. However, trials in patients with AML will ultimately be required to assess the therapeutic window of this combination. We further assessed the activity of this drug combination on AML stem cells using clonogenic growth assays. Primary AML cells were treated with parthenolide and vildagliptin alone or in combination, and the cells were then plated into colony formation assays. Vildagliptin enhanced parthenolide's ability to reduce the clonogenic growth of the tested primary AML samples by 29-39% (Supplementary Table 1 ). In addition, we tested the effects of the parthenolide/vildagliptin combination by engrafting primary AML cells into immune-deficient mice. Ex vivo AML patient cells were treated with the combination, individual drugs, or a DMSO control and injected into the right femur of preconditioned NOD-SCID mice. Following a 4-week engraftment period, mice were killed and the percentage of AML cells in the non-injected femur was measured by flow cytometry. The parthenolide/vildagliptin combination decreased leukemia stem cell engraftment compared with either drug alone and completely eliminated the Figure 2d ). Collectively, these results demonstrate that the combination of vildagliptin and parthenolide can target AML stem cells.
Vildagliptin's enhancement of parthenolide's cytotoxicity is independent of its known target DPPIV Vildagliptin's known target as an oral anti-hyperglycemic is DPPIV, 17 but the mechanism by which it synergized with parthenolide was unclear. Therefore, we asked whether vildagliptin's synergy with parthenolide was mediated through the known target DPPIV. To evaluate the potential role of DPPIV in mediating the synergistic effects, we measured the expression of cell surface DPPIV in TEX cells by flow cytometry. DPPIV is absent from the surface of TEX and OCI-AML2 cells. In contrast, we determined that OCI-Ly17 cells, a human lymphoma cell line, express DPPIV ( Figure 3a) ; however, these cells do not show synergy with this drug combination (Figure 3b ). Confirming the findings by flow cytometry, a DPPIV enzymatic assay also demonstrated no DPPIV activity on TEX cells (Figure 3c) . Finally, to confirm that inhibition of DPPIV is not related to vildagliptin's enhancement of parthenolide's activity, we assessed the combination of parthenolide and sitagliptin, a more selective inhibitor of DPPIV. 18 Here, TEX or OCI-AML2 cells were treated with parthenolide and/ or sitagliptin and following 72 h of incubation, cell growth and viability were measured by the MTS assay. In contrast to the synergistic combination with vildagliptin, the selective DPPIV inhibitor sitagliptin did not increase the antileukemic activity of parthenolide (Figure 3d , two-way ANOVA, interaction effect: F 2,6 ¼ 0.36; P ¼ 0.786). Thus, taken together, these results demonstrate that vildagliptin's synergy with parthenolide occurs through mechanisms unrelated to DPPIV inhibition.
Vildagliptin's synergy with parthenolide is mediated through inhibition of intracellular DPP8 and DPP9 The DPPIV gene family consists of several members that include DPPs IV, 8 and 9 and fibroblast activation protein. 19 DPPs IV, 8 and 9 share sequence homology, and vildagliptin inhibits the enzymatic activity of DPP8 (K I ¼ 810 nM), DPP9 (K I ¼ 95 nM) and DPPIV (K I ¼ 3 nM). 20 We therefore assessed whether the inhibition of DPP8 or DPP9 was responsible for vildagliptin's enhancement of parthenolide's cytotoxicity.
As an initial step, we evaluated the expression of DPPs IV, 8 and 9 in TEX, OCI-AML 2 cells and normal bone marrow. Both AML cell lines expressed DPP8 and DPP9, but had little expression of DPPIV compared with normal marrow (Figure 4a ). We also compared four publicly available microarray data sets [21] [22] [23] [24] to determine whether DPP8 and DPP9 were elevated in CD34 þ /CD38 À leukemia cells compared with normal hematopoietic cells. Most but not all data sets demonstrated increased expression of DPP8 or DPP9 in AML stem cells compared with normal hematopoietic cells (Supplementary Table 2 ).
Next, we assessed the effects of parthenolide treatment on expression of DPP8 and DPP9 in OCI-AML2 and TEX cells. Treatment with parthenolide at concentrations that synergize with vildagliptin did not alter the mRNA expression of either DPP8 or DPP9 in OCI-AML2 or TEX cells (Figure 4b) . Finally, we knocked down DPP8 and DPP9 to determine the potential role of these targets in mediating vildagliptin's synergy with parthenolide. We knocked down DPP8 and DPP9 in OCI-AML2 cells using shRNA in lentiviral vectors. We were unsuccessful in knocking down these proteins in TEX cells. Knockdown of DPP8 or DPP9 with two independent shRNA clones per target was confirmed using quantitative reverse transcriptase PCR (qRT-PCR) (Panel I : Figures 4c and d) . Next, we treated DPP8 or DPP9 knockdown cells with parthenolide. Knockdown of DPP8 and DPP9 increased sensitivity to parthenolide compared with cells infected with vector controls (Panel II: one-way ANOVA: DPP8: Figure 4d ). However, the enhancement of cytotoxicity did not fully mimic the effect of vildagliptin. Moreover, when these single knockdown cells (that is, devoid in either DPP8 or DPP9) were treated with parthenolide and vildagliptin, a significant increase in cell death was still observed when compared with parthenolide treatment alone (Panel III: DPP8: clone 8-417, t 4 ¼ 6.5, Po0.05; clone 8-647, t 4 ¼ 6.8, Po0.01; DPP9: clone 9-2315, t 4 ¼ 4.7, Po0.01; clone 9-2871, t 4 ¼ 20.4; Po0.005; Figures 4c and d) . Thus, these results suggest that knockdown of DPP8 or DPP9 can enhance the cytotoxicity of parthenolide, but the single knockdown of either is insufficient to fully recapitulate the effects of vildagliptin.
We therefore hypothesized that vildagliptin enhances parthenolide's cytotoxicity by inhibiting both DPP8 and DPP9. To test this hypothesis, DPP8 and DPP9 were simultaneously knocked down in OCI-AML2 cells using shRNA in lentiviral vectors. Target knockdown was confirmed using qRT-PCR (Figure 5a ). Significant enhancement of cytotoxicity was observed when DPP8 and DPP9 double knockdown cells were treated with parthenolide, and the magnitude of effect matched that of vildagliptin (Figure 5b,  Supplementary Figure 3) . Moreover, the addition of vildagliptin did not produce further cell death in DPP8 and DPP9 knockdown cells treated with parthenolide (Figure 5b) . Thus, these results indicate that vildagliptin's synergy with parthenolide is mediated through the inhibition of both DPP8 and DPP9.
DISCUSSION
Combination screening determined vildagliptin synergistically enhanced parthenolide's anti-leukemic activity. This combination was effective in primary AML samples including the stem cell fraction. Mechanistically, we determined that synergy was through vildagliptin's inhibition of intracellular DPP8 and DPP9.
Vildagliptin is used clinically as an oral anti-hyperglycemic for the treatment of diabetes. As such, the pharmacokinetics of vildagliptin has been well-studied. It is rapidly absorbed (t max ¼ 1.1 h) and rapidly excreted (elimination t 1/2 ¼ 1.6-2.5 h) with a reported absolute bioavailability of B85%, following a 100-mg single oral dose. 20 Renal elimination and analysis showed that 22-29% of excreted vildagliptin is unchanged (that is, not metabolized) and 4.5% of unchanged drug was excreted in the feces. 25 In healthy patients, a 200-mg single oral dose achieved 95% DPPIV inhibition and no adverse reactions or toxicities were observed; AUC of 5.7 ± 0.6 mg.h/ml (equivalent of 18 mM), Cmax 1.3±0.26 mg/ml and peak plasma concentrations at 1.5 h were reported. 26 Further, in a two-year trial with patients with type 2 diabetes mellitus, 50 mg vildagliptin tablets twice daily were associated with minimal adverse effects (for example, dizziness, nausea in less than 12% of the study participants, n ¼ 396). 27 Thus, given the favorable pharmacokinetic data for the treatment of hyperglycemia, vildagliptin concentrations (10 mM) necessary to synergize with parthenolide to induce leukemia cell cytotoxicity appear pharmacologically achievable and generally well-tolerated.
Vildagliptin's inhibition of DPPIV is well-documented in its role as an oral anti-hyperglyemic. However, as an anti-cancer agent we determined that vildagliptin's activity, in combination with parthenolide, is independent of DPPIV. Instead, we demonstrate that vildagliptin's synergy with parthenolide occurs through inhibition of intracellular DPP8 and DPP9. A limitation to this study is that we could not evaluate expression of DPPs 8 and 9 by immunoblotting. All commercially available antibodies crossreacted with many non-specific proteins and the identity of the DPP8 and DPP9 proteins could not be determined with certainty.
However, DPPIV shares 21 and 20% sequence homology with DPP8 and DPP9, respectively, 28 and vildagliptin inhibits the enzymatic activity of all enzymes of the DPPIV gene family. 20 Therefore, given the sequence similarity and cross-reactivity of vildagliptin with all members of the DPPIV gene family of enzymes, vildagliptin's synergy with parthenolide through vildagliptin's inhibition of DPP8 and DPP9 is a highly plausible mechanism.
The DPPIV family of enzymes are ubiquitously expressed and are found in immune and epithelial cells of the brain, blood, lung, spleen and testes. [29] [30] [31] DPPIV cleaves a number of substrates including chemokines, glucagon-like peptides, stromal-derived factor 1 (CXCL12) and RANTES. 17 In addition to its role in regulating insulin levels by inactivating the incretin hormones, DPPIV, as a component of CD26, exerts a level of cellular protection. For example, DPPIV protects against ischemia-induced tissue damage by promoting adenosine metabolism through its binding of adenosine deaminase. 32, 33 However, the intracellular functions of DPP8 and DPP9 are less clear. A role in modifying cellextracellular matrix interactions has been suggested, but there is limited in vivo or human data and few DPP8 and DPP9 substrates have been identified. 34 A recent study demonstrated a role in cellular proliferation, as DPP8 and DPP9 affect EGF receptor signaling through inhibition of AKT phosphorylation. 19 Although the function of DPP8 and DPP9 remain to be elucidated, these enzymes are elevated in numerous hematological malignancies. Patients with B-cell chronic lymphocytic leukemia had elevated mRNA and protein levels of DPP8 and DPP9; 35 plasma DPP activity was elevated in 80 and 62% in patients with lymphoid leukemia and AML, respectively. 36 These elevated DPP levels suggest these enzymes may have a role in leukemia pathogenesis, and are thus valuable therapeutic targets.
The mechanism by which vildagliptin's inhibition of DPP8 and DPP9 enhances parthenolide's cytotoxicity remains to be elucidated. However, vildagliptin's inhibition of DPP8 and DPP9 was specific to parthenolide, as the cytotoxicity of other conventional therapeutics (that is, cytarbine, vinblastine and doxorubicin) was not enhanced by the addition of vildagliptin. Potentially, vildagliptin influences one or more of the cell signaling pathways perturbed by parthenolide. Indeed, parthenolide has been demonstrated to inhibit NFkB by binding to IkB-kinase, modify p50 and p65 NFkB subunits, activate p53, block STAT 3 phosphorylation and increase the production of reactive oxygen species. [4] [5] [6] [7] [8] However, targeting of one these pathways alone is insufficient to induce cell death. For example, treatment of AML blasts with NFkB decoy oligonucleotides did not elicit an apoptotic response; apoptosis did occur when cytarabine was added in combination with the decoy oligonucleotides; 37 and cellular anti-oxidant status determines sensitivity to parthenolide, as only myeloma and hepatoma cells with low levels of catalase 38 or glutathione, 37 respectively, were sensitive to parthenolideinduced cell death. Finally, a number of studies demonstrate that numerous drugs (for example, mTOR inhibitors, TRAIL, paclitaxel, sulindac) with various targets combine with parthenolide to induce cancer cell death, 9, 39, 40 which further supports the notion that multiple cellular processes are involved in parthenolideinduced cell death. Therefore, it is likely that the inhibition of DPP8 and DPP9 by vildagliptin adds further stress to parthenolidetreated leukemia cells, thus enhancing its overall cytotoxicity.
In summary, a high-throughput screen identified vildagliptin, an oral anti-hyperglycemic drug used in the treatment of diabetes, as a drug capable of synergistically enhancing parthenolide's antileukemia activity. Mechanistically, vildagliptin's basis for synergy with parthenolide was through vildagliptin's inhibition of the intracellular enzymes DPP8 and DPP9. Future studies are needed to evaluate the safety of the parthenolide/vildagliptin combination.
